Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years.
Nick Paul Taylor
Oct 29, 2024 6:16am
Novartis inks $150M deal for autoimmune molecular glue
Oct 28, 2024 7:00am
New drugs reduce parasites in crypto-infected mice and calves
Oct 25, 2024 11:12am
Novartis pays Baiyu $70M, with $1.1B chaser, for cancer prospect
Oct 17, 2024 8:17am
Novartis channels Gargamel, terminating midphase SMURF1 trial
Oct 14, 2024 9:14am
Generate gains another $1B-plus Big Pharma partner in Novartis
Sep 24, 2024 6:00am
